Appeal No. 95-0155
Application No. 07/890,335
through 90, and 92 through 96, which are all of the claims
remaining in the application.
REPRESENTATIVE CLAIMS
Claims 69 and 95, which are illustrative of the subject
matter on appeal, read as follows:
69. A method of treatment or prophylaxis of thrombosis,
embolism or other conditions where it is desired to produce
fibrinolytic or proteolytic activity selectively in the
presence of fibrin via the mechanism of plasminogen activation
which comprises administering by injection or intravenously to
a patient a plasminogen activator composition comprising a
plasminogen activator component, said component being a human
tPA/human pro-tPA couple composed of from 70 to 100% human
pro-tPA and from 0 to 30% human tPA.
95. A pharmaceutical composition suitable for the
treatment or prophylaxis of thrombosis or embolism which
composition acts selectively in the presence of fibrin by
means of local plasminogen activation and which is in dosage
units for injection or intravenous infusion, said composition
comprising:
(a) a human tPA/human pro-tPA couple composed of 70-100%
human pro-tPA and up to 30% human tPA; and
(b) a physiologically compatible medium.
THE REFERENCES
In rejecting all of the appealed claims under 35 U.S.C.
§ 103, the examiner relies on the following reference:
Collen et al. 0 041 766 Dec. 16, 1981
(European Patent Application)
-2-
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007